Last reviewed · How we verify
Methylnaltrexone treatment
At a glance
| Generic name | Methylnaltrexone treatment |
|---|---|
| Sponsor | Asbjørn Mohr Drewes |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RELISTOR's Effects on Opioid-Induced Constipation
- Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics (NA)
- Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation (PHASE4)
- Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis (PHASE2, PHASE3)
- Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids (PHASE4)
- An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer (PHASE3)
- A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer (PHASE2, PHASE3)
- Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylnaltrexone treatment CI brief — competitive landscape report
- Methylnaltrexone treatment updates RSS · CI watch RSS
- Asbjørn Mohr Drewes portfolio CI